[go: up one dir, main page]

WO2006074187A3 - Method of treating brain cancer - Google Patents

Method of treating brain cancer Download PDF

Info

Publication number
WO2006074187A3
WO2006074187A3 PCT/US2006/000122 US2006000122W WO2006074187A3 WO 2006074187 A3 WO2006074187 A3 WO 2006074187A3 US 2006000122 W US2006000122 W US 2006000122W WO 2006074187 A3 WO2006074187 A3 WO 2006074187A3
Authority
WO
WIPO (PCT)
Prior art keywords
brain cancer
treating brain
compounds
quinazolines
caspases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/000122
Other languages
French (fr)
Other versions
WO2006074187A2 (en
Inventor
Sui Xiong Cai
Mark B Anderson
Adam Willardsen
Nilantha Sudath Sirisoma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myriad Genetics Inc
Cytovia Therapeutics LLC
Original Assignee
Myriad Genetics Inc
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc, Cytovia Inc filed Critical Myriad Genetics Inc
Priority to CA002592971A priority Critical patent/CA2592971A1/en
Priority to AU2006204052A priority patent/AU2006204052A1/en
Priority to EP06717342A priority patent/EP1833511A4/en
Priority to JP2007549710A priority patent/JP2008526776A/en
Publication of WO2006074187A2 publication Critical patent/WO2006074187A2/en
Priority to US11/773,285 priority patent/US8258145B2/en
Anticipated expiration legal-status Critical
Publication of WO2006074187A3 publication Critical patent/WO2006074187A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs, and in particular to the use of these compounds in treating brain cancer.
PCT/US2006/000122 2005-01-03 2006-01-03 Method of treating brain cancer Ceased WO2006074187A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002592971A CA2592971A1 (en) 2005-01-03 2006-01-03 Method of treating brain cancer
AU2006204052A AU2006204052A1 (en) 2005-01-03 2006-01-03 Method of treating brain cancer
EP06717342A EP1833511A4 (en) 2005-01-03 2006-01-03 METHOD OF TREATING BRAIN CANCER
JP2007549710A JP2008526776A (en) 2005-01-03 2006-01-03 Brain cancer treatment methods
US11/773,285 US8258145B2 (en) 2005-01-03 2007-07-03 Method of treating brain cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64126305P 2005-01-03 2005-01-03
US60/641,263 2005-01-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/773,285 Continuation US8258145B2 (en) 2005-01-03 2007-07-03 Method of treating brain cancer

Publications (2)

Publication Number Publication Date
WO2006074187A2 WO2006074187A2 (en) 2006-07-13
WO2006074187A3 true WO2006074187A3 (en) 2008-01-10

Family

ID=36648123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/000122 Ceased WO2006074187A2 (en) 2005-01-03 2006-01-03 Method of treating brain cancer

Country Status (7)

Country Link
EP (1) EP1833511A4 (en)
JP (1) JP2008526776A (en)
KR (1) KR20070117547A (en)
CN (1) CN101287369A (en)
AU (1) AU2006204052A1 (en)
CA (1) CA2592971A1 (en)
WO (1) WO2006074187A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
AU2008236995A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
CN101742910A (en) * 2007-04-10 2010-06-16 美瑞德制药公司 Method of treating brain cancer
FR2932180B1 (en) * 2008-06-04 2012-08-10 Centre Nat Rech Scient DIHYDRO ISO CA-4 AND THE LIKE: CYTOTOXICALLY POWERFUL, INHIBITORS OF TUBULIN POLYMERIZATION
CN103380142A (en) 2011-03-15 2013-10-30 奇斯药制品公司 Isoxazolidine derivatives
AU2012228334B2 (en) 2011-03-15 2017-03-23 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
FR3019819B1 (en) * 2014-04-09 2018-03-23 Centre National De La Recherche Scientifique (Cnrs) CYTOTOXIC COMPOUNDS INHIBITING TUBULIN POLYMERIZATION
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
WO2019201848A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
FR3080620B1 (en) * 2018-04-27 2021-11-12 Univ Paris Sud COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES
CN117440954A (en) * 2021-04-20 2024-01-23 田纳西大学研究基金会 Metabolically stable pyrimidinyldihydroquinoxalinone as a tubulin polymerization inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005297A1 (en) * 1987-12-03 1989-06-15 Smithkline Beckman Intercredit B.V. Compounds
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
US6284764B1 (en) * 1999-01-27 2001-09-04 Pfizer Inc. Substituted bicyclic derivatives useful as anticancer agents
US6552027B2 (en) * 1998-05-28 2003-04-22 Parker Hughes Institute Quinazolines for treating brain tumor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071484T3 (en) * 1991-02-20 1995-06-16 Pfizer DERIVATIVES OF 2,4-DIAMINOQUINAZOLINAS TO INCREASE ANTITUMORAL ACTIVITY.
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
JP2008505907A (en) * 2004-07-06 2008-02-28 アンジオン バイオメディカ コーポレイション Quinazoline modulators that modulate hepatocyte growth factor and c-met activity for cancer therapy
EP1833482A4 (en) * 2005-01-03 2011-02-16 Myriad Genetics Inc NITROGEN BICYCLIC COMPOUNDS AND THERAPEUTIC USE THEREOF

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005297A1 (en) * 1987-12-03 1989-06-15 Smithkline Beckman Intercredit B.V. Compounds
WO1998010767A2 (en) * 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
US6552027B2 (en) * 1998-05-28 2003-04-22 Parker Hughes Institute Quinazolines for treating brain tumor
US6284764B1 (en) * 1999-01-27 2001-09-04 Pfizer Inc. Substituted bicyclic derivatives useful as anticancer agents

Also Published As

Publication number Publication date
WO2006074187A2 (en) 2006-07-13
EP1833511A4 (en) 2011-01-19
KR20070117547A (en) 2007-12-12
EP1833511A2 (en) 2007-09-19
CN101287369A (en) 2008-10-15
JP2008526776A (en) 2008-07-24
CA2592971A1 (en) 2006-07-13
AU2006204052A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
WO2005003100A3 (en) 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A3 (en) Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2006135915A3 (en) Methods and compositions for treating degenerative bone disorders
WO2006138511A3 (en) Use of hif 1alfa modulators for treatment of cancer
WO2008100384A3 (en) Activin-actriia antagonists and uses for promoting bone growth in cancer patients
TW200519202A (en) Modulation of eIF4E expression
IL233634A0 (en) Methods, compositions, and kits for the treatment of medical conditions
WO2008155533A3 (en) Phenothiazine compounds for treating mild cognitive impairment
TW200740804A (en) Glucokinase activators
MX2009006536A (en) Organic compounds and their uses.
WO2009126786A3 (en) Improved quenching methods for red blood cell pathogen inactivation
TNSN08400A1 (en) Organic compounds and their uses
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
ZA200802848B (en) Potassium channel inhibitors
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
EA201100874A1 (en) COMPOUNDS FOR CANCER TREATMENT
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
WO2006074187A3 (en) Method of treating brain cancer
MX2008015775A (en) Compounds and compositions for treatment of cancer.
IL177437A0 (en) Ctgf as target for the therapy of diabetic nephropathy
WO2008033887A3 (en) Methods for treating cancer
TW200738143A (en) Use of arylanilides for seed treatment
WO2006074223A3 (en) Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
WO2011118928A3 (en) Pharmaceutical composition for preventing or treating heart failure and method for screening agent for preventing or treating heart failure
WO2010065861A3 (en) Inhibitors of bace 1 and methods for treating alzheimer's disease

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680002525.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006204052

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 556040

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006717342

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007549710

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2592971

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11773285

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006204052

Country of ref document: AU

Date of ref document: 20060103

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077017960

Country of ref document: KR